Member Info for LemonsToRiches

Https://www.linkedin.com/posts/mark-eccleston-48382a_happy-to-be-back-in-boston-for-immune-oncology-activity-7310110431879090177-yCW9

Https://www.linkedin.com/posts/invhub_activity-7356598583573295106-Xy8C

This page shows just the senior Ambrose staff and consultant advisors, count them up and you'll see how incorrect Ray is.

https://www.ambrosehc.com/our-team

I suggest reading their profiles too.

I've checked the file and it's not ancient at all, it's only from 29 May 2024, barely a year old and no doubt intended for use at conferences for the rest of last year as a minimum.

As for how many staff Ambrose have, Ray doesn't know that what is stated in the presentation is incorrect, they don't lie like he obviously does, they state the position of their company as a matter of transparency, as they have nothing to hide, there's certainly nothing to gain by saying they had more or less staff than they actually have, it's the products that other companies are interested in not how many Beakers they have.

Facts that are of no value to investors you mean.

Ray appears to like raising points that are of no importance, I guess that's because he can't find anything relevant to argue about.

The three points I raised are still relevant.

Ambrose will still be targeting £170m p.a. revenues from 401, that won't have changed, there's no reason why it would change.

They are still targeting a cap of £800m, that won't change either, it's their core business plan.

They mention companies like them and VAL being bought out for upwards of $952m (three examples). That won't change either, it's already happened.

Ambrose did a presentation where they said they are targeting £170m p.a. revenues from 401.

They also said they are targeting a cap of £800m where they'll exit (sell off the company). Targeting a 5 year exit with 30x ROI for investors.

They mention companies like them and VAL being bought out for upwards of $952m (three examples).

https://www.anglonordiclifescience.com/uploads/3905/presentations/ambrose-healthcare-afternoon-session-biotech-room-1.pdf

Also, a press article says they are targeting creating a new HQ and IPO in the Middle East. That would be one way to quickly raise huge money, including the £16m to pay VAL. Getting the 401 agreement in place could be the trigger point for that IPO, as they've had the plan since 2023 but now have the product agreement to solidify the prospectus.

https://www.agbi.com/manufacturing/2023/04/uk-pharma-startup-targets-gulf-for-future-ipo/

Hope it turns out that you are OK.

On VAL, £1,000 in here now could be £100,000 within a year or two. (£2.25m cap to £250m cap is £1,000 into £111,111). Quite doable and sometimes Mark is aiming for (in fact he mentioned on the webcast a similar company going to £350m).

I think Ambrose will pop up with some cash they've raised soon.

It takes a few weeks to secure cash that was promised to be invested on signing of the agreement with VAL, so it's getting closer by the day.

I think Mark would have stipulated before signing the agreement that VAL needed cash from Ambrose as soon as they could raise it, a bit of pressure on Ambrose to help out their partner as it were. The deal includes up to £6m in cash, this is where I think Mark would have made it clear he'd much prefer cash and soon.

Ambrose have financial backers. With the VAL agreement signed off, they have two choices, one is to issue stock to VAL which VAL would then sell, the other is to issue shares to their financial backers who would much prefer that and keep hold of the stock. Some of the money from selling shares to their financial backers would be given to VAL and everyone is happy.

If they put just £2m of cash into VAL coffers it'll double or triple the share price because funding risk evaporates. £6m in and those Warrants could be up for exercising, something Mark said was one of his primary targets

"The initial £6 million milestones are payable in cash or the equivalent value in new ordinary shares in Ambrose with the issue price determined by the latest issue of shares in Ambrose, at the discretion of Ambrose. Payment of milestones in cash is subject to Ambrose raising capital in due course."

What price a cure? Big money no doubt.

"There is currently no known cure for hemangiosarcoma, an aggressive cancer in dogs, according to the American Veterinary Medical Association. While treatments like surgery and chemotherapy can help prolong life and improve quality of life, they do not offer a cure. Hemangiosarcoma is a particularly challenging cancer due to its aggressive nature and tendency to spread rapidly."

"The prognosis for hemangiosarcoma is generally poor, with median survival times ranging from a few months to a year, even with aggressive treatment. The specific prognosis depends on factors like the tumor's location, whether it has metastasized, and the effectiveness of treatment."

Luckybob23,

Nobody is trying to sell it, what they are doing is making it easier for others to understand without having to read 100 times that amount of information. If anyone doesn't feel the need to read such information for one reason or another, nobody is forcing them to do so.

Paternostpauper,

Thanks and likewise with your posts.

When life gives you lemons, make lemonade.

Waveygravey538,

Why? Because I understand?

Anyone that can be bothered to do some valid research on this company would know the same as I do, they don't need to work for the company to understand.

Looking at the chart doesn't tell people where it's heading next, understanding it's business journey and current business position tells people where it's heading.

Significant progress was made with Cytolytix during the period. A new stable, liposomal formulation was developed and evaluated as part of an ongoing formulation evaluation program. Three further formulations are under development with specific characteristics suited for particular routes of administration and final selection is expected in Q2 2025. Initial data showing efficacy in Prostate Cancer cell lines was obtained with grant funding through our Academic Partner at the Open University.

The in-house research pipeline comprised 4 evaluation programmes with assets from Barcelona University, Stingray Bio, Imperial College and Dundee University as well as our SPV Cytolytix. The pipeline represented a range of early stage, small molecule and peptide-based assets with a combination of validated, novel and unknown mechanisms of action. Assets at this stage of development have a high attrition rate, up to 90%. Development of in-licensed assets, for example Cytolytix, through preclinical development and into Investigational New Drug (IND) enabling studies, take significant time and resources so a high attrition rate should be expected with earlier stage programmes. A key consideration is to generate a balanced portfolio with scientifically robust data and a strong commercialisation potential and, going forward, we are applying a strict set of criteria for selection and progression of evaluation assets. Evaluation agreements with Barcelona and, post period Imperial, have been terminated despite initially promising data generated by Inaphaea, as they did not meet these criteria. Whilst the Dundee evaluation did not meet a key decision point for in-licensing in 2024, £50,000 grant funding was secured through Queen Mary Impact fund, supported and a one-year extension to the evaluation agreement was signed to develop precise mechanism of action for this asset. The Stingray evaluation was completed on time and, whilst a key decision point was not reached, we are in further negotiation to progress this asset under a slightly different model.

Several new evaluation programmes remained under discussion throughout 2024 with the first signed post period in January 2025. The agreement with Altus Therapeutics is based on repositioning an established CB2 agonist in oncology and, in a first for ValiRx, bringing new formulation capabilities. A key aspect of the evaluation programmes is to leverage Inaphaea's in-house capabilities. Inevitably, some of the work will require external support, either through our partner network or from additional Contract Research Organisations which can add significant costs. This is particularly true for later stage, more developed projects which may be lower risk but require higher initial investment. In order to deliver a more balanced portfolio, we are exploring shorter, more nimble evaluations over a 3-6-month period where we can add significant value through our PDC biobank or through support of external preclinical work on a shared risk, costs plus basis. Under this type of arrangement, ValiRx would be compensated for work performed if the asset is returned and subsequently licensed.

Continued in next post.

Restrictions on supplying PDCs to competitive service providers were removed, recognising a significant opportunity to build value through supplying CROs with established client bases. Several additional co-marketing agreements are under discussion and expected to be signed in 2025. A simplified pricing structure was introduced for direct purchase of the PDCs focussed on commercial research and commercial service use with options for annual payment, one off payment and limited use licenses for one off services.

In addition to the commercial partnerships, ValiRx secured additional grant funding to support development and characterisation of Prostate Cancer PDCs through its established academic partnership with the Open University. This relationship was strengthened with a ValiRx sponsored PhD studentship over four years to develop high value, Neuroendocrine Prostate Cancer Cell lines. These lines represent a significant development for the field, particularly in the development of new drugs in this highly aggressive form of prostate cancer. This academic collaboration is expected to lead to publications exemplifying the utility of the PDC models as well as additional grant applications, following a model we established at the ValiRx spin out Volition. Further academic partnerships are being explored with universities local to Inaphaea. These new relationships are a cost-effective approach to leverage access to specialist facilities to add further value to our Biobank, including cell sorting and characterisation.

In addition to development of products and services based on the Biobank, the second key objective for Inaphaea was the provision of rapid and flexible initial assessment for each of the evaluation programmes as well as development of Cytolytix. Both exemplify how we have leveraged Inaphaea's commercial and academic partner network, established as part of the tCRO® service offering, for example, in-silico toxicity screening of the Stingray compounds and peptide formulation and screening of CLX001.

Continued in next post.

as part of the group operational review, we also looked at inaphaea's business model. inaphaea saw some significant milestones throughout 2024 including the signing of two, multiphase, service contracts including its first us contract. this immune-oncology focussed service contract leveraged inaphaea's biobank rna-seq data for the selection of patient derived cell models with high pd-l1 checkpoint expression. the second contract, with a total potential value of over £100,000, was focussed on triple negative breast cancer pdcs and builds on biobank development work carried out to support the in house cytolytix program. this second contract demonstrates the value of partner strategy with the final optional part of the multiphase project to be performed by one of inaphaea's in-vivo partners. the pipeline of client prospects within inaphaea is looking strong, with a steady build of prospects throughout the second half of 2024. although the nature of our industry is of long-term research budget planning with associated long lead times, our current pipeline of prospects is progressing well. as the catalogue of characterised pdcs is developed we expect this to grow further with product license as well as service opportunities.

the second half of 2024 saw a rapid expansion of the evaluation and co-marketing approach to include a range of in-vivo and ex vivo partners, broadening both capabilities and global market reach. the partnerships are set up as "force multipliers" to expand lead identification of new potential clients whilst providing the opportunity to offer extended service packages that leverage inaphaea's pdc models. we added new partner capabilities including in-silico toxicity testing, "system on a chip" 3d models, patient derived organoid models as well as higher throughput zebra fish and standard mouse models. the expansion of access to sophisticated, ex-vivo predictive systems, builds on key features of the "closer to patient", more representative pdc biobank with its combination of cancer cells and cancer associated fibroblasts (cafs). this heterogeneity differentiates our pdc models from standard, ****geneous cell lines and was a key driver for the development of our assay ready reagent product line. these vials of mixed cells are designed for direct biomarker analysis, with the first sale achieved in november 2024 with the combined bank of 5,000 vials underpinning the value of the biobank as a major asset. the development of more sophisticated screening capabilities, in keeping with the 3r principles of replacement, reduction and refinement for ethical animal research, is a key market opportunity supported by the fda's significant announcement to phase out animal testing post period in april 2025.

continued in next post.

Mark is not responsible for any loss of value in VAL, he is the one turning the company around. If that turnaround is too slow for the greedy short term traders then bog off somewhere else with your tripe. Mark will make this company a huge success and worth huge multiples of it's currently hugely undervalued price.

What caused the drop over years before Mark arrived is there for all to see, as are the changes Mark has instigated to turn the company around long term. With the state the company was in, it was never going to be an overnight reversal of the valuation, but everything he has done and is doing means that NOW is the right time to load up, BEFORE it goes on a long term upwards trend.

Chairman's Report for the year ended 31 December 2023

The last few years are widely acknowledged to have been challenging for the biotech industry across the board and specifically for publicly listed companies. Investor interest has significantly retreated, most likely driven by a combination of geo-political events and the dramatic rise in interest rates to tackle high inflation.

Not surprisingly, ValiRx has not been immune to these external factors, further exacerbated by slower than expected progress in key projects, such as VAL201 out-licencing and, to a lesser extent, protracted negotiations on university-derived evaluation agreements.

..................

Chairman and Chief Executives Report for the year ended 31 December 2024

In our first joint Annual report, we would like to take the opportunity to review a significant year of transition for ValiRx.

The transition was initiated by several changes to the Board, including the appointments of a new Chairman and CEO followed by the appointment of Cathy Tralau-Stewart, our Chief Scientific Officer, to the Executive Board in August 2024.

We then undertook an immediate review of the business focussing on the scientific and commercial strategy and business model for Inaphaea Biolabs Limited ("Inaphaea"), a wholly owned subsidiary of the Company. The outcome of this review was implemented across the second half of the year and into the first quarter of 2025. In addition to identifying several cost-reduction measures involving external service providers, we faced the difficult decision to restructure the organisation. This restructuring aimed to optimise efficiency and reduce cash burn, which unfortunately led to fewer available positions within the Company. In December 2024, the Inaphaea team was reduced by one Senior Scientist, and, after a redundancy consultation process, three additional positions were eliminated across the Group post-period end.

Continued in next post

A dose of BS from a VAL stock basher you mean.

Money is made by investing in the future, not the past. The future of VAL is massive upside potential.

When Mark took over, the company was in bad shape and stuck in a three year downward spiral from 48p. His job was to reorganise the company, which he has now completed. His job was to cut out wasted time on drugs that didn't make the cut, which he has done. His job was to focus on drugs that had a high chance of success and to build partnerships that benefitted those developments, which he has done and is still doing. His job was to cut cash burn to reasonable and acceptable levels, which he has done. His job was to generate revenue from partnerships, which he has done and is still doing.

Stock bashers will always try to trick people into looking at the past, when only the future matters in investing, don't be mugged off by the deception.

The market doesn't seem to understand how big just one drug could be for VAL, it is completely underestimating the potential here. Look at the deal GSK announced yesterday, the figures for just one drug are eye watering, for 12 drugs, mind blowing!

"GSK shares rise on $500m drug deal with China’s Hengrui"

Shares in GSK PLC (LSE:GSK, NYSE:GSK) rose in morning trading after the pharmaceutical group announced a $500 million collaboration with Hengrui Pharma to co-develop up to 12 experimental medicines, in a deal that could be worth as much as $12 billion.

The agreement includes global rights (excluding China and a few territories) to HRS-9821, a potential new treatment for chronic obstructive pulmonary disease (COPD).

The drug targets enzymes that drive inflammation and airway tightening, with early studies showing improved lung function. It will be developed as a dry-powder inhaler, complementing GSK’s existing respiratory portfolio.

Beyond HRS-9821, the deal gives GSK the option to license up to 11 more drug candidates.

Hengrui will lead early development through phase I trials, with GSK taking over later-stage development and global commercial rights.

If all milestones are met, Hengrui could receive up to $12 billion in total payments, plus royalties on future product sales.